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Comparison of Docetaxel- and Vinca Alkaloid–Based
Chemotherapy in the First-line Treatment of Advanced
Non-small Cell Lung Cancer: A Meta-analysis of Seven
Randomized Clinical Trials
Jean-Yves Douillard, MD, PhD,* Silvy Laporte, PhD,† Frank Fossella, MD,‡
Vassilis Georgoulias, MD, PhD,§ Jean-Louis Pujol, MD, Kaoru Kubota, MD,¶ Alain Monnier, MD,#
Shinzoh Kudoh, MD,** Jaime Ernesto Rubio, MD,†† and Michel Cucherat, MD, PhD‡‡
Introduction: To compare the impact on overall survival (OS) of
docetaxel-based chemotherapy versus vinca alkaloid–based regi-
mens for first-line therapy of advanced non-small cell lung cancer.
Methods: A meta-analysis of all randomized, controlled trials com-
paring docetaxel- and vinca alkaloid–based chemotherapy was un-
dertaken using MEDLINE, CANCERLIT, MEDSCAPE, Google
Scholar, the Cochrane Library, the National Institutes of Health
randomized, controlled trials register, and conference proceedings,
supplemented by information from clinical study reports. All pub-
lished and unpublished randomized, controlled trials (in any lan-
guage) were included. Analysis was based on pooling individual loga-
rithms of the hazard ratio for OS and the odds ratio (OR) for safety.
Results: From eight potentially eligible trials, seven were selected
(n  2867). Docetaxel was administered with a platinum agent
(three trials), with gemcitabine (two trials), or as monotherapy (two
trials). Vinca alkaloid (vinorelbine [six trials] and vindesine [one
trial]) was administered with cisplatin (six trials) or alone (one trial).
The pooled estimate for OS showed an 11% improvement in favor
of docetaxel (hazard ratio  0.89; 95% confidence interval: 0.82–
0.96; p  0.004). Sensitivity analyses considering only vinorelbine
as a comparator or only the doublet regimens showed similar
improvements. Grade 3/4 neutropenia and grade 3/4 serious adverse
events were less frequent with docetaxel- versus vinca alkaloid–
based regimens (OR  0.59; 95% confidence interval: 0.38–0.89;
p 0.013 and OR 0.68; 95% confidence interval: 0.55–0.84; p
0.001, respectively).
Conclusion: According to this meta-analysis, docetaxel is superior
to vinca alkaloid–based regimens in terms of OS and safety for
first-line therapy of advanced non-small cell lung cancer.
(J Thorac Oncol. 2007;2: 939–946)
Lung cancer is the leading cause of cancer and cancer-related deaths worldwide, with 1.2 million deaths annually.1
Non-small cell lung cancer (NSCLC), which accounts for
approximately 80% of lung cancer cases, presents as local
disease in 20% to 30% of patients and as advanced metastatic
disease (stage IIIb/IV) in 40% to 50%.2 Platinum-based
doublet regimens are considered the standard first-line treat-
ment for advanced NSCLC.3–5
Newer, so-called third-generation chemotherapy agents,
including docetaxel, paclitaxel, vinorelbine, and gemcitabine,
have improved outcomes in advanced NSCLC compared with
older agents.6 Vinorelbine was the first agent to show a survival
benefit when combined with cisplatin7 and consequently became
a standard regimen for the first-line treatment of NSCLC.
Combinations of a vinca alkaloid (vinorelbine and
vindesine) and cisplatin have yielded response rates from
19% to 43% and median survival times from 8 to 10
months.7–12 Several randomized trials and one meta-analysis
have attempted to compare the different third-generation
chemotherapy agents.8,9,13–17 Among these comparative stud-
ies of docetaxel- and vinca alkaloid–based chemotherapy,
some have suggested that differences in activity may exist
between the treatments, particularly in terms of survival.
However, a cross-trial comparison of these studies is not
possible because of differences in trial design, dose regimens,
and patient characteristics and thus may not provide reliable
conclusions. Furthermore, some trials may be underpowered
to detect differences between treatment groups in survival
and safety outcomes if they are powered for surrogate end-
points such as tumor response or time to progression. To
provide a more statistically powerful method of cross-trial
*Centre R. Gauducheau, St. Herblain, France; †Clinical Pharmacology
Department, Centre Hospitalier Universitaire, Saint-Etienne, France;
‡University of Texas M.D. Anderson Cancer Center, Houston, Texas;
§University General Hospital of Iraklion, Heraklion, Greece; Centre
Hospitalier Universitaire, Montpellier, France; ¶National Cancer Center
Hospital, Kashiwa, Chiba, Japan; #Centre Hospitalier A. Bouloche,
Montbeliard, France; **Osaka City General Hospital, Osaka, Japan;
††Centro Medico National de Occ, Guadalajara Jalisco, Mexico; and
‡‡Centre Hospitalier Universitaire, Lyon, France.
Disclosure: The authors declare no conflict of interest.
Address for correspondence: Jean-Yves Douillard, MD, PhD, Centre Rene´
Gauducheau, Boulevard J. Monod, 44805 Saint Herblain, France. E-mail:
jy-douillard@nantes.fnclcc.fr
Presented at American Society of Clinical Oncology 2006 and European
Society for Medical Oncology 2006.
Copyright © 2007 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/07/0210-0939
Journal of Thoracic Oncology • Volume 2, Number 10, October 2007 939
comparison and detecting treatment differences,18,19 a meta-
analysis was performed. Data from docetaxel- and vinca
alkaloid–based regimens were compared for the first-line
treatment of advanced NSCLC using all relevant published
and unpublished randomized, controlled trials (RCTs).
MATERIALS AND METHODS
Literature Search and Study Identification
Our aim was to identify all relevant published and
unpublished RCTs comparing docetaxel- and vinca alkaloid–
based chemotherapy regimens for the first-line treatment of
advanced NSCLC. An exhaustive literature search, both man-
ual and computer assisted, was performed without any re-
striction on language or dates.
The computer-assisted search was carried out on elec-
tronic databases (MEDLINE, CANCERLIT, MEDSCAPE,
Google Scholar, the Cochrane Library, and the National
Institutes of Health RCT register [clinicaltrials.org] using the
terms non-small cell lung cancer or NSCLC; phase II, phase
III, randomized, controlled, or meta-analysis; docetaxel or
Taxotere, in combination with generic and trade names of the
vinca alkaloids. In addition, conference proceedings from the
American Society of Clinical Oncology (ASCO), the Euro-
pean Society for Medical Oncology, and the European Can-
cer Conference were searched for abstracts of relevant trials.
We manually searched the bibliographies of journal articles
to find additional studies. Particular attention was given to
duplicate reports, and, when studies were published both in
abstract form and as an original article, only the article was
referenced. If more than one article was published for a single
study, all citations were included.
Study Selection
We selected randomized trials evaluating the effect of
docetaxel compared with a vinca alkaloid as first-line che-
motherapy for advanced NSCLC. All trials had to include one
or more treatment arm with docetaxel alone, or combined
with either a platinum agent (cisplatin or carboplatin) or
gemcitabine, and one or more vinca alkaloid–based treatment
arm. Studies including the administration of granulocyte
colony-stimulating factor (G-CSF) were considered. When a
trial was deemed eligible, all investigators and sponsors were
systematically contacted and asked to provide the protocol
and clinical and statistical study reports because detailed
statistical information (i.e., log of the hazard ratio [HR] and
the variance) is required for meta-analyses of survival out-
comes.20
Assessment of Study Quality
The methodologic quality of each trial was classified
according to the Jadad score.21 This score incorporates as-
sessments of randomization, proper generation and conceal-
ment of the treatment allocation sequence, blinding of pa-
tients and investigators, and completeness of follow-up
(based on information for withdrawals and dropouts). To be
included in this analysis, studies had to achieve a Jadad score
2, in effect excluding trials that did not involve proper
randomization procedures (i.e., studies without concealment
of randomization). Because all studies were open-label trials,
as is common in oncology, the blinding items were system-
atically not filled in.
Data Extraction
Predefined data from individual trials were extracted
independently by two of the authors (M.C., S.L.). A concor-
dance meeting was held, and, in case of a discrepancy in
either study selection or data extraction, agreement was
reached. The following data were extracted: name of the first
author and study acronym, year(s) of publication, number of
randomized patients, study design, study quality (Jadad
score), treatment regimens, duration of follow-up, and effi-
cacy and safety endpoints (overall survival [OS]; grade 3/4
neutropenia; febrile neutropenia; grade 3/4 serious adverse
events [SAEs]; SAEs leading to discontinuation of the drug;
and SAEs leading to death). Data were directly extracted
from the protocol and clinical and statistical reports.
Statistical Analysis
The efficacy analysis was performed on an intent-to-
treat basis. Analysis of survival was based on the pooling of
individual logarithms of the HR. Summary data were pooled
by the inverse-variance weighting method.22 When the HR
was missing and the life table was not available, an HR was
calculated from the number of deaths and the log-rank p value
(four decimal places). An HR of 1 indicated that there was no
difference between the treatments, an HR 1 indicated that
docetaxel was superior to the vinca alkaloid, and an HR 1
indicated that the vinca alkaloid was superior. Safety analyses
were based on the safety population in each trial. A pooled
safety outcome was based on the logarithm of the odds ratio
(OR) weighted by the inverse of the variance. An OR of 1
indicated that there was no difference between the treatments,
an OR 1 indicated that docetaxel was less toxic than the
vinca alkaloid, and an OR 1 indicated that the vinca
alkaloid was less toxic.
To investigate the statistical heterogeneity between
trials, the standard Q test was applied (meaningful differences
in treatment effect between studies indicated by p  0.10).
The results were generated using the fixed-effects model
unless otherwise stated. When there was evidence of signif-
icant statistical heterogeneity (and in the absence of a clear
explanation for heterogeneity), a random-effects model was
employed, generating a more conservative estimate.23
A funnel plot of treatment effect versus study precision
was created for the primary endpoint to detect publication
bias.19,24 Such a technique is potentially helpful in determin-
ing whether additional small studies may have been con-
ducted but not published because of unfavorable or negative
results and therefore not identified for the meta-analysis.
Subgroup analyses were performed for the combination
of docetaxel with a platinum agent or gemcitabine, or as
monotherapy. Sensitivity analyses (planned a priori) were
performed to further establish the robustness of the results for
the primary endpoint—first, when considering only do-
cetaxel-based regimens versus the vinorelbine comparator
and, second, when considering only docetaxel-doublet regi-
mens. An additional a posteriori sensitivity analysis was
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performed when considering only trials comparing docetaxel
with vinca alkaloid administered via matching regimens (both
alone or both with the same concomitant chemotherapy).
Finally, to identify any study that may have exerted a
disproportionate influence on the summary treatment effect,
we deleted studies one at a time from the analysis. Statistical
analyses were performed using the computer program
easyMA (Department of Clinical Pharmacology, Cardiolog-
ical Hospital, Lyon, France).25
RESULTS
Study Selection
Eight RCTs were identified as potentially eligible for
inclusion.14–16,26–30 One trial comparing docetaxel plus car-
boplatin versus vinorelbine plus carboplatin in 60 patients
was excluded30 because we did not have access to the study
protocol or randomization schedule, resulting in a Jadad score
2. However, a print version of all individual case report
forms (CRFs) was provided by the principal investigator and
an additional sensitivity analysis was performed including
this trial. The inclusion and exclusion criteria, study design,
and principal outcomes for each study included in the meta-
analysis are shown in Table 1. Finally the reports for all the
remaining trials were available to extract the data on survival
and safety outcomes.
Study Design
Seven trials were available, including 2867 patients
(Table 1). The largest trial was carried out mainly in the
United States, Canada, and Europe. Two trials were per-
formed in Japan, two in France, one in Greece, and one in
Europe (mainly in Eastern Europe [Russia and the Czech
Republic]). The age range of patients included in all studies
was 22 to 87 years. One trial was performed in elderly
patients (median age, 76 years). Of the enrolled populations,
the proportion of males ranged from 66% to 88%.
One of the studies was a three-arm trial.14 In the
absence of a clear methodologic consensus, the two compar-
isons derived from this trial were considered separately with-
out in-trial adjustment of the alpha risk for multiplicity. Four
comparisons were available for docetaxel plus a platinum
agent (cisplatin or carboplatin), two for docetaxel plus gem-
citabine, and two for docetaxel alone (restricted either to
elderly patients16 or to a population selected based on the
presence of a potential biologic marker29) (Table 1). The
doses of docetaxel varied from 60 mg/m2 to 100 mg/m2.
The vinca alkaloid component included vinorelbine in six
trials and vindesine in one trial (3 mg/m2). The doses of
vinorelbine varied from 25 mg/m2 to 30 mg/m2. Four trials
reported the use of G-CSF in the treatment groups.
Study Quality and Publication Bias
All the trials were open label. Appropriate methods
were used to generate the randomized treatment allocations,
which appeared to be adequately concealed in all studies.
Withdrawals and dropouts were available for five trials,
yielding a Jadad score of 3. The funnel plot of effect size was
symmetrical, with a similar number of studies on either side
of the summary treatment effect (data not shown), indicating
a lack of major publication bias.
Overall Survival
The HR for each trial and the corresponding confidence
intervals (CIs) for OS are shown in Figure 1. Individual HRs
ranged from 0.75 to 1.00. The pooled estimate for OS showed
a significant 11% improvement in favor of docetaxel (HR 
0.89; 95% CI: 0.82–0.96; p  0.004) (Figure 1). No signif-
icant heterogeneity was found between the trials for OS. The
results for all drug combinations favored docetaxel, with an
HR of 0.87 (95% CI: 0.79–0.96) for docetaxel combined
with a platinum agent; 0.89 (95% CI: 0.82–0.96) for non-
platinum-based docetaxel regimens; 0.96 (95% CI: 0.81–
1.13) for docetaxel combined with gemcitabine; and 0.87
(95% CI: 0.69–1.09) for docetaxel monotherapy.
OS benefit was similar when considering only vinorel-
bine trials (HR  0.91; 95% CI: 0.83–0.98), only doublet
regimens (HR  0.89; 95% CI: 0.82–0.97), or only trials
with matching regimens14–16,26 (HR  0.82; 95% CI: 0.73–
0.92). Any uncertainty about the effect of excluding the
Rubio and Sahagun trial30 due to the lack of access to the
study protocol was ruled out by the secondary evaluation,
which showed no change from the original results. Finally,
removing individual studies from the analysis did not alter the
result: for example, when excluding the largest trial (Fossella
et al.14), the result for the primary endpoint (OS) remained
significant (HR  0.88; 95% CI: 0.79–0.98).
Neutropenia
All individual study results for grade 3/4 neutropenia
favored docetaxel except for the Kudoh et al. trial,16 which
compared single-agent docetaxel with a vinorelbine mono-
therapy regimen with a rather low-dose intensity schedule.
Thus, heterogeneity between trials was observed (heteroge-
neity test p  0.005). After exclusion of the Kudoh et al.16
study, the results consistently favored docetaxel, irrespective
of which combination was used. Finally, a random-effects
model was used to calculate the overall estimate including
all trials. A significant reduction in grade 3/4 neutropenia
was observed in favor of docetaxel, with a significant 41%
reduction in the number of events versus the vinca alkaloid
comparator (OR  0.59; 95% CI: 0.38 – 0.89; p  0.013)
(Figure 2A).
Similar results were observed for febrile neutropenia,
with a significant 43% reduction in the number of events in
favor of docetaxel compared with vinca alkaloids (OR 
0.57; 95% CI: 0.35–0.94; p  0.028) (Figure 2B).
Serious Adverse Events
When considering grade 3/4 SAEs, the results favored
docetaxel, with a significant 32% reduction in the number of
events versus the vinca alkaloid (OR  0.68; 95% CI:
0.55–0.84; p  0.001; Figure 3). There was both a reduction
in SAEs leading to study drug discontinuation (OR  0.61;
95% CI: 0.34–1.10; p  0.10) and in SAEs leading to death
with docetaxel (OR  0.76; 95% CI: 0.48–1.21; p  0.25)
(Figure 3).
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Dose Intensity and G-CSF Use
Median dose intensities varied from 75% to 98% for
docetaxel, from 65% to 90% for the vinca alkaloids, and from
74% to 100% for cisplatin (Table 2). The use of G-CSF was
comparable between groups (Table 2).
DISCUSSION
The results of this meta-analysis (2867 patients from
seven RCTs) show that docetaxel-based regimens statistically
significantly improve survival compared with vinca alkaloid
regimens for first-line therapy of advanced NSCLC. This
benefit in OS for docetaxel was accompanied by an improved
safety profile compared with vinca alkaloids, with a signifi-
cant reduction in grade 3/4 SAEs and febrile neutropenia. The
improvements in safety were obtained without increasing the
use of G-CSF or decreasing the dose intensity in the do-
cetaxel arm compared with the vinca alkaloid arm.
Improvements in OS and safety might have been ex-
pected to be associated with an improvement in overall
quality of life. Unfortunately, only some of the trials in this
meta-analysis included a formal quality-of-life assessment,
and when a quality-of-life assessment was included, the
scales used were different and hence the data could not be
pooled.
Several points associated with the methodology used in
this meta-analysis are worth noting. First, the absence of
significant heterogeneity between trials in terms of OS led to
consistent results, as the benefit in OS was always in favor of
docetaxel-based regimens compared with vinca alkaloids.
Second, the sensitivity analyses confirmed the consistent
results in favor of docetaxel whether comparing docetaxel-
with vinorelbine-based regimens, considering only docetaxel
administered in doublet regimens, or including only trials
with matching regimens. In 1997, ASCO recommendations
advocated that chemotherapy for NSCLC patients should
consist of a platinum-based combination regimen.31 The
ASCO recommendations were revised in 2003 to include
nonplatinum-containing chemotherapy regimens as an alter-
native to platinum-based regimens for first-line treatment,
and single-agent chemotherapy in elderly patients or patients
with an Eastern Cooperative Oncology Group performance
status of 2.4 These guidelines are currently the standard of
care for NSCLC in the United States and Europe, where
similar recommendations have been adopted.32 Consider-
ing some of the different treatment options for patients
with advanced NSCLC, this meta-analysis shows that OS
was significantly improved with docetaxel plus a platinum
agent (HR  0.87; 95% CI: 0.79 – 0.96) as well as with
nonplatinum-based docetaxel regimens (HR  0.89; 95%
CI: 0.82– 0.96).
To minimize publication bias in this meta-analysis,33
data from published and unpublished trials were included.
Although the risk of publication bias exists in any meta-
analysis, whether based on individual patient data or not, the
symmetrical funnel plot indicated that this was not a major
concern in our study. Furthermore, as the use of third-
generation agents for NSCLC is a fairly recent development,
the risk of omitting data was reduced.
Although this meta-analysis was not performed on
individual patient data, neither was it solely based on pub-
lished data. The quality of data was improved by obtaining
clinical and statistical reports from the authors or sponsors of
all included trials. As the primary aim of the study was to
assess the robust clinical endpoints of OS and safety, it is
unlikely that individual patient data would have provided
additional value. However, further investigations using indi-
vidual patient data are warranted to provide more detailed
FIGURE 1. Overall survival for each
of the seven trials included in the
meta-analysis and the total pooled
estimate, showing 95% CIs. An HR
1 (on the left of the black line)
corresponds to results in favor of
docetaxel. No heterogeneity was
observed between trials. *Adjusted
HR for important prognostic vari-
ables. Cb, carboplatin; CI, confi-
dence interval; HR, hazard ratio.
Journal of Thoracic Oncology • Volume 2, Number 10, October 2007 Meta-analysis of Chemotherapy in NSCLC
Copyright © 2007 by the International Association for the Study of Lung Cancer 943
analyses in specific subgroups of patients and to examine
additional endpoints.34
Following the exhaustive research of data, a mix of
phase II and III RCTs has been considered here. Although the
phase II studies may have been too small to produce reliable
survival data, no significant heterogeneity was observed in
OS among the trials included in the analysis. This result
supports the decision to include all randomized phase II or III
trials with prospectively recorded survival data.
During the past 10 years, several NSCLC meta-analy-
ses have been published.6,17,35–43 As the NSCLC Group
meta-analysis published in 1995 has demonstrated, the con-
tribution of meta-analyses to the treatment of patients with
NSCLC has been very important in illustrating the impact of
chemotherapy on survival.5,44 Such studies have helped to
define a two-drug platinum-based regimen as the gold-standard
treatment for NSCLC.3–5 Recently, in the meta-analysis pub-
lished by Le Chevalier et al.,17 gemcitabine plus platinum
regimens resulted in a 7% reduction in overall mortality versus
other third-generation drugs combined with a platinum com-
pound. No data on safety were analyzed in this meta-analysis of
gemcitabine trials.17 However, the comparison between gemcit-
abine-based platinum regimens and docetaxel-based platinum
regimens has not been assessed by any meta-analysis as yet, and
further studies are required to analyze the benefit:risk ratio of
docetaxel with that of other comparators.
Our meta-analysis shows that some significant benefits
exist for docetaxel- versus vinca alkaloid–based regimens for
first-line therapy of advanced NSCLC, including a survival
benefit. Docetaxel-based regimens were also associated with
FIGURE 2. (A) Grade 3/4 neutrope-
nia for each of the seven trials in-
cluded in the meta-analysis and the
total pooled estimate, showing 95%
CIs. An OR 1 (on the left of the
black line) corresponds to results in
favor of docetaxel. No heterogeneity
was observed between trials using
the random-effects model. (B) Fe-
brile neutropenia for each of the
seven trials included in the meta-
analysis and the total pooled esti-
mate, showing 95% CIs. An OR 1
(on the left of the black line) corre-
sponds to results in favor of do-
cetaxel. No heterogeneity was ob-
served between trials using the
random-effects model. Cb, carbopla-
tin; CI, confidence interval; n.a, not
available; OR, odds ratio.
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a more favorable safety profile than vinorelbine- or vin-
desine-based combination regimens. These findings may be
helpful when choosing an appropriate therapy for advanced
NSCLC, with the aim of improving survival without increas-
ing the toxicity profile. The improved efficacy and safety
profile of docetaxel-based regimens compared with vinca
alkaloid-based regimens is very encouraging, and such regi-
mens may provide a potential platform on which to add
targeted therapies for first-line treatment in the future.
Since the present analysis was performed, two addi-
tional trials were presented at ASCO 2007 as posters. One
phase III from the Hellenic Oncology Research Group45
compared a combination of oral vinorelbine-gemcitabine
with docetaxel-gemcitabine in 254 patients. The results show
no difference on survival but a trend in favor of the docetaxel-
gemcitabine arm. The second study also from the same
group46 in elderly patients evaluated the use of vinorelbine
versus docetaxel as single agents in 112 patients in a phase II
setting. No statistical difference was observed in survival,
with again a trend in favor of docetaxel. Less myelosuppres-
sion was seen with docetaxel. These two additional trials
show results in the same direction that our meta-analysis
favoring the use of docetaxel but were underpowered to reach
their objectives.
In conclusion, docetaxel-containing regimens provided
a statistically significant reduction in the risk of death and
toxicity for patients with advanced NSCLC when compared
with vinca alkaloid–containing regimens.
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